Mirati Therapeutics, Inc.
DelistedCIK 1576263fmd_1K6TESXZCQHW5X9CTFXQTA4FF1Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2012 to Sep 30, 2023, 46 periods
| Line item | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | 0 | 0 | 13 | 3 | 13 | 72 | 12 |
| Research and development | 20 | 26 | 49 | 68 | 58 | 94 | 183 | 299 | 509 | 532 |
| Selling, general and administrative | – | – | – | – | – | – | – | 83 | 137 | 240 |
| Total operating expenses | 32 | 39 | 65 | 84 | 72 | 116 | 225 | 383 | 645 | 772 |
| Operating income | (32) | (39) | (65) | (84) | (72) | (103) | (222) | (369) | (573) | (760) |
| Interest and investment income | 0 | – | – | – | – | – | – | – | – | – |
| Other non-operating income (expense) | (1) | (0) | 0 | 1 | 1 | 4 | 9 | 11 | (5) | 19 |
| Income before taxes | (53) | (44) | (65) | (83) | (70) | (98) | (213) | (358) | (578) | (740) |
| Income tax expense | (0) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 1 |
| Net income from continuing operations | (53) | (44) | (65) | (83) | (70) | (98) | (213) | (358) | (582) | (741) |
| Net income | (53) | (44) | (65) | (83) | (70) | (98) | (213) | (358) | (582) | (741) |